Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Sector: Healthcare Industry: Biotechnology CIK: 0001178670
P/B 243.01
P/E 1,304.71
P/S 17.71
Market Cap 56.84 Bn
ROIC (Qtr) 8.13
Div Yield % 0.00
Rev 1y % (Qtr) 149.35
Total Debt (Qtr) 3.21 Bn
Debt/Equity (Qtr) 13.74

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 1.49B provide 9.29x coverage of short-term debt 160.45M, demonstrating strong liquidity position and minimal refinancing risk.
  • Robust free cash flow of 221.36M exceeds capital expenditure of 44.50M by 4.97x, indicating strong organic growth funding capability.
  • Tangible assets of 4.85B provide exceptional 1909.35x coverage of deferred revenue 2.54M, showing strong service capability backing.
  • Operating cash flow of 265.86M provides strong 104.63x coverage of deferred revenue 2.54M, indicating service delivery capability.
  • Operating cash flow of 265.86M fully covers other non-current liabilities 7.23M by 36.78x, showing strong long-term stability.

Cons

  • Operating cash flow of 265.86M barely covers its investment activities of 420.58M, with a coverage ratio of 0.63, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 420.58M provide weak support for R&D spending of 1.25B, which is 0.34x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • High receivables of 964.77M relative to inventory of 75.38M (12.80 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • The company's operating cash flow of 265.86M shows concerning coverage of stock compensation expenses of 368.25M, with a 0.72 ratio indicating potential earnings quality issues.
  • Operating cash flow of 265.86M provides minimal -3.52x coverage of tax expenses of (75.51M), suggesting potential tax planning inefficiencies or unsustainable tax positions.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,377.82 Bn -1,495.00 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 442.39 Bn 6,453.60 88.96 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 114.19 Bn 31.07 9.74 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 76.52 Bn 16.71 5.37 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 56.84 Bn 1,304.71 17.71 3.21 Bn
6 ARGX Argenx Se 53.58 Bn 35.57 27,941.68 -
7 BNTC Benitec Biopharma Inc. 44.65 Bn -1,067.50 0.00 0.00 Bn
8 INSM INSMED Inc 36.43 Bn -30.77 81.49 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 11.93 12.31
EV to Cash from Ops. 217.79 23.25
EV to Debt 18.02 738.44
EV to EBIT 444.31 -9.16
EV to EBITDA 202.24 6.95
EV to Free Cash Flow [EV/FCF] 261.57 21.90
EV to Market Cap 1.04 65.67
EV to Revenue 18.04 227.32
Price to Book Value [P/B] 238.86 22.34
Price to Earnings [P/E] 1,282.42 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.80 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -9.90 -27.13
Cash and Equivalents Growth (1y) % 35.49 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 8.09 -46.93
EBITDA Growth (1y) % 273.91 -1.68
EBIT Growth (1y) % 169.73 -56.45
EBT Growth (1y) % 90.05 -12.70
EPS Growth (1y) % 111.88 -28.31
FCF Growth (1y) % 1,278.10 -31.90
Gross Profit Growth (1y) % 50.59 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.66 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 0.96 3.85
Current Ratio 2.54 7.27
Debt to Equity Ratio 13.74 0.40
Interest Cover Ratio 0.80 841.00
Times Interest Earned 0.80 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 4.70 -18,234.31
EBIT Margin % 4.06 -18,580.80
EBT Margin % -1.00 -19,488.74
Gross Margin % 83.90 -7.59
Net Profit Margin % 1.40 -19,439.22